Supplemental NDA for stronger version of Advair deemed "not approvable"

A GlaxoSmithKline supplemental NDA for a stronger version of asthma drug Advair Diskus for use in treating patients with chronic obstructive pulmonary disease, recommended for approval by an FDA advisory committee, has been deemed “not approvable” in another apparent show of agency independence from its outside panels.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions